BioMarin Plans to Divest Struggling Gene Therapy - The Fritsma Factor

Oct 28 2025

George Fritsma

Thanks to Dean Willett of Precision BioLogic Inc. for the heads-up on BioMarin’s 10-27-25 post announcing their divestment of the hemophilia A gene transfer therapy, Roctavian. See BioMarin’s 10-27 press release.

Comments (0)

Bleeding Disorders

No comments here.

Leave a Reply Cancel reply

You must be logged in to post a comment.

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question